Interestingly, the authors noted that, although the study was not able to evaluate risks for specific cancers, 19 patients in the anti-TNF-α group had received this therapy after a melanoma diagnosis, with 4 experiencing a recurrence [16]. This evidence concerns the gene TNF and melanoma.